Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
All LSBio Custom kits have been predesigned and all necessary components, including antibodies and standards have been identified. Upon receiving a custom kit order, the kit will be assembled and quality control tested before being shipped out. Kit assembly and testing typically takes 4 to 6 weeks. In most cases the final kit is based on the Sandwich assay principle, with a few being Competitive EIA based. Specifications such as Range, Sensitivity, and Precision are defined upon completion. In the event that the custom kit cannot be successfully developed with 6 weeks of the order date, the customer will be notified and the order canceled at no cost.
LIG1 / DNA Ligase 1
LS-F20328 is a 96-well enzyme-linked immunosorbent assay (ELISA) for the detection of Human LIG1 / DNA Ligase 1. It is based upon a Custom assay principle.
LIG1 ElisaKit, DNA ligase I ElisaKit, DNA ligase 1 ElisaKit, Ligase I, DNA, ATP-dependent ElisaKit
LIG1 / DNA Ligase 1 is a member of the ATP-dependent DNA ligase protein family. The encoded protein functions in DNA replication, recombination, and the base excision repair process. Mutations in this gene that lead to DNA ligase I deficiency result in immunodeficiency and increased sensitivity to DNA-damaging agents. Disruption of this gene may also be associated with a variety of cancers. Alternative splicing results in multiple transcript variants.